VANDA PHARMACEUTICALS INC. Cash and Restricted Cash
VANDA PHARMACEUTICALS INC. (VNDA) had Cash and Restricted Cash of $56.35 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56.35M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $54.50M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85.32M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.49M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $56.35M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $54.50M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $85.32M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $70.49M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $81.45M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $112.27M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $102.78M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $100.97M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $103.42M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $125.63M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $136.29M 10-K · filed 2026-02-12 |
| 2023-09-30 | $183.66M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $150.50M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $354.64M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $135.50M 10-K · filed 2026-02-12 |
| 2022-09-30 | $49.87M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $58.74M 10-Q · filed 2023-07-28 |
| 2022-03-31 | $67.44M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $52.59M 10-K · filed 2025-02-14 |
| 2021-09-30 | $51.04M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $57.82M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $72.71M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $61.61M 10-K · filed 2024-02-08 |
| 2020-09-30 | $57.55M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $95.88M 10-Q · filed 2021-07-29 |
| 2020-03-31 | $65.53M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $45.65M 10-K · filed 2023-02-09 |
| 2019-09-30 | $39.95M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $47.29M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $35.12M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $61.75M 10-K · filed 2022-02-24 |
| 2018-09-30 | $61.52M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $61.63M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $156.04M 10-Q · filed 2019-05-03 |
| 2017-12-31 | $34.34M 10-K · filed 2021-02-11 |
| 2017-09-30 | $23.42M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $15.06M 10-Q · filed 2018-08-02 |
| 2017-03-31 | $20.94M 10-Q · filed 2018-05-02 |
| 2016-12-31 | $41.26M 10-K · filed 2020-02-26 |
| 2015-12-31 | $51.63M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |